News
J&J jumps on the MFN pricing train
Johnson & Johnson is the latest pharma group to agree a Most-Favoured Nation (MFN) drug pricing deal with the Trump administration to avert tariffs.
Sales & Marketing
Sponsored
How to meet your physicians where they are online
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
R&D
Deep Dive: Research and Development 2025
Every breakthrough in medicine, every new treatment that changes lives, starts with research.
Sales & Marketing
Sponsored
The strategic imperative of Integrated Evidence Generation P...
Integrated Evidence Generation Planning (IEGP) is recognised as a strategic necessity for biopharmaceutical organisations.
R&D
Shaping the future of immunodeficiency care, with Dr Jörg Sc...
Dr Jörg Schüttrumpf, Chief Scientific Innovation Officer of Grifols, discusses advancing immunoglobulin (or IG) treatment for immune disorders.
R&D
Sponsored
A New Framework to Engineer Breakthrough Value for Medicines
A new white paper from Lumanity – ‘A New Framework to Engineer Breakthrough Value for Medicines: Value Inflection Points Across the Development Path’.
Market Access
VuuAI and Amiculum partner to transform content engagement i...
Amiculum, a global health communications agency, has entered into an exciting strategic collaboration with VuuAI, a GenAI-driven content production automation plat
R&D
Partner Content
5th mRNA-Based Therapeutics Summit Europe
The Summit is the leading European industry-focused forum dedicated to accelerating the development of messenger RNA (mRNA) medicines